Vascular cognitive impairment: Epidemiology, subtypes, diagnosis and management

Journal of the Royal College of Physicians of Edinburgh

Volumn 41, Issue 1, 2011, Pages 49-56

  Black, S E ^a  

^a North and East Greater Toronto Area   (Canada)

Author keywords

Amyloid angiopathy; Cholinesterase inhibitors; Cognitive testing; Overt and silent stroke; Vascular dementia; White matter hyperintensities

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EXECUTIVE FUNCTION; HEART INFARCTION; HUMAN; LIFESTYLE; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; RISK FACTOR; SCREENING; STROKE; VASCULAR COGNITIVE IMPAIRMENT;

AGED; BRAIN INFARCTION; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA, MULTI-INFARCT; DEMENTIA, VASCULAR; HUMANS; STROKE;

EID: 79959494228     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2011.121     Document Type: Article

References (62)

1. Hachinski VC. Multi-infarct dementia: a reappraisal. Alzheimer Dis Assoc Disord 1991; 5:64-8. doi:10.1097/00002093-199100520-00002
2. O'Brien JT, Erkinjuntti T, Reisberg B et al. Vascular cognitive impairment. Lancet Neurol 2003; 2:89-98. doi:10.1016/S1474- 4422(03)00305-3
3. Rockwood K, Wentzel C, Hachinski V et al. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 2000; 54:447-51.
4. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ 1994; 150:899-913.
5. Rocca WA, Hofman A, Brayne C et al. The prevalence of vascular dementia in Europe: facts and fragments from 1980-1990 studies. Ann Neurol 1991; 30:817-24. doi:10.1002/ana.410300611
6. Kase CS, Wolf PA, Chodosh EH et al. Prevalence of silent stroke in patients presenting with initial stroke: the Framingham Study. Stroke 1989; 20:850-2.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association; 1994.
8. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-44.
9. Román GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology 1993; 43:250-60.
10. Gold G, Bouras C, Canuto A et al. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry 2002; 159:82-7. doi:10.1176/appi.ajp.159.1.82
11. Greicius MD, Srivastava G, Reiss AL et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004; 101:4637-42.doi:10.1073/pnas.0308627101
12. Tatemichi TK, Desmond DW, Mayeux R et al. Dementia after stroke: Baseline frequency, risks and clinical features in a hospitalized cohort. Neurology 1992; 42:1185-93.
13. Desmond DW, Moroney JT, Sano M et al. Incidence of dementia after ischemic stroke: results of a longitudinal study. Stroke 2002; 33:2254-60. doi:10.1161/01.STR.0000028235.91778.95
14. Pohjasvaara T, Leppävuori A, Siira I et al. Frequency and clinical determinants of poststroke depression. Stroke 1998; 29:2311-7.
15. Herrmann N, Black SE, Lawrence J et al. The Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcome. Stroke 1998; 29:618-24.
16. Pohjasvaara T, Erkinjuntti T, Vataja R et al. Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years. Stroke 1997; 28:729-35.
17. Swartz RH, Black SE. Anterior-medial thalamic lesions in dementia: frequent, and volume dependently associated with sudden cognitive decline. J Neurol Neurosurg Psychiatry 2006; 77:1307-12.doi:10.1136/jnnp.2006.091561
18. Black S, Gao F, Bilbao J. Understanding white matter disease: imaging-pathological correlations in vascular cognitive impairment. Stroke 2009; 40:S48-S52. doi:10.1161/STROKEAHA.108.537704
19. Longstreth WT Jr, Bernick C, Manolio TA et al. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998; 55:1217-25. doi:10.1001/archneur.55.9.1217
20. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007; 6:611-9. doi:10.1016/ S1474-4422(07)70170-9
21. DeCarli C, Massaro J, Harvey D et al. Measures of brain morphology and infarction in the Framingham Heart Study: establishing what is normal. Neurobiol Aging 2005; 26:491-510. doi:10.1016/j.neurobiolaging.2004.05.004
22. Longstreth WT Jr, Dulberg C, Manolio TA et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2002; 33:2376-82. doi:10.1161/01.STR.0000032241.58727.49
23. Bernick C, Kuller L, Dulberg C et al. Silent MRI infarcts and the risk of future stroke: the Cardiovascular Health Study. Neurology 2001; 9; 57:1222-9.
24. Vermeer SE, den Heijer T, Koudstaal PJ et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003; 34:392-6. doi:10.1161/01.STR.0000052631.98405.15
25. Thore CR, Anstrom JA, Moody DM et al. Morphometric analysis of arteriolar tortuosity in human cerebral white matter of preterm, young, and aged subjects. J Neuropathol Exp Neurol 2007; 66: 337-45.doi:10.1097/nen.0b013e3180537147
26. Holland CM, Smith EE, Csapo I et al. Spatial distribution of whitematter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke 2008; 39:1127-33.doi:10.1161/ STROKEAHA.107.497438
27. Thompson CS, Hakim AM. Living beyond our physiological means: small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke 2009; 40:e322-e330.doi:10.1161/STROKEAHA.108.542266
28. Moody DM, Brown WR, Challa VR et al. Periventricular venous collagenosis: association with leukoaraiosis. Radiology 1995; 194:469-76.
29. Longstreth WT, Manolio TA, Arnold AM et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke 1996; 27:1274-82.
30. De Groot JC, de Leeuw FE, Oudkerk M et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000; 47:145-51. doi:10.1002/1531-8249(200002)47:2<145::AIDANA3> 3.0.CO;2-P
31. DeCarli C, Murphy DGM, Tranh M et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995; 45:2077-84.
32. Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322:1447-51. doi:10.1136/bmj.322.7300.1447
33. Launer LJ, Ross GW, Petrovitch H et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21:49-55. doi:10.1016/S0197-4580(00)00096-8
34. Arvanitakis Z, Wilson RS, Bienias JL et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61:661-6. doi:10.1001/archneur.61.5.661
35. Slooter AJ, Cruts M, Kalmijn S et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998; 55:964-8. doi:10.1001/ archneur.55.7.964
36. Snowdon DA, Greiner LH, Mortimer JA et al. Brain infarction and the clinical expression of Alzheimer disease.The Nun Study. JAMA 1997; 277:813-7.
37. Schneider JA, Arvanitakis Z, Bang W et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69:2197-204. doi:10.1212/01. wnl.0000271090.28148.24
38. Lim A, Tsuang D, Kukull W et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 1999; 47:564-9.
39. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001; 357:169-75. doi:10.1016/S0140- 6736(00)03589-3
40. Hansen LA, Samuel W. Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology 1997; 48:126-32.
41. De la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33:1152-62. doi:10.1161/01. STR.0000014421.15948.67
42. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82:239-59.doi:10.1007/BF00308809
43. Pettersen JA, Sathiyamoorthy G, Gao FQ et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook Dementia Study. Arch Neurol 2008;65:790-5. doi:10.1001/archneur.65.6.790
44. Johnson KA, Gregas M, Becker JA et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62:229-34. doi:10.1002/ana.21164
45. Cordonnier C. Brain microbleeds. Pract Neurol 2010;10:94-100. doi:10.1136/jnnp.2010.206086
46. Lindsay P, Bayley M, McDonald A et al. Toward a more effective approach to stroke: Canadian best practice recommendations for stroke care. CMAJ 2008; 20; 178:1418-25.
47. Hachinski V, Iadecola C, Petersen RC et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37:2220-41. doi:10.1161/01.STR.0000237236.88823.47
48. Folstein MF, Folstein SE, McHugh PR. 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98. doi:10.1016/0022-3956(75)90026-6
49. Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695-9. doi:10.1111/ j.1532-5415.2005.53221.x
50. Erkinjuntti T. Subcortical ischemic vascular disease and dementia. Int Psychogeriatr 2003;15 (Suppl 1):23-6. doi:10.1017/ S1041610203008925
51. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13:S115-S123. doi:10.1097/00002093-199912003-00017
52. Perry E, Ziabreva I, Perry R et al. Absence of cholinergic deficits in 'pure' vascular dementia. Neurology 2005; 64:132-3.
53. Swartz RH, Sahlas DJ, Black SE. Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintensities matter? J Stroke Cerebrovasc Dis 2003; 12:29-36. doi:10.1053/jscd.2003.5
54. Bocti C, Swartz RH, Gao FQ et al. A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke 2005; 36:2126-31. doi:10.1161/01. STR.0000183615.07936.b6
55. Erkinjuntti T, Kurz A, Gauthier S et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359:1283-90. doi:10.1016/S0140-6736(02)08267-3
56. Auchus AP, Brashear HR, Salloway S et al. Galantamine treatment of vascular dementia: a randomised trial. Neurology 2007; 69:448-58. doi:10.1212/01.wnl.0000266625.31615.f6
57. Black S, Román GC, Geldmacher DS et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34:2323-30.doi:10.1161/01. STR.0000091396.95360.E1
58. Wilkinson D, Doody R, Helme R et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61:479-86.
59. Román GC, Wilkinson DG, Doody RS et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005; 20:338-44. doi:10.1159/000088494
60. Román GC, Salloway S, Black SE et al. Randomized, placebocontrolled, clinical trial of donepezil in vascular dementia. Differential effects by hippocampal size. Stroke 2010; 41:1213-21.doi:10.1161/STROKEAHA.109.570077
61. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebocontrolled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17:297-305.doi:10.1097/00004850-200211000-00005
62. Orgogozo JM, Rigaud AS, Stoffler A et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834-9. doi:10.1161/01.STR.0000020094.08790.49